Compare Amphastar Pharmaceuticals Inc (AMPH) vs Huntington Ingalls Industries Inc (HII) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

HII trades at $286.09, down 0.04% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows stable profitability with a 4.71% net margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights ongoing naval contracts and shipbuilding milestones, supporting revenue visibility from its $54 billion backlog.

The stock presents a value opportunity with a P/E of 18.59 and P/S of 0.88 below industry averages, alongside a 44% analyst buy rating and a $384.50 price target implying significant upside. Risks include defense budget dependency and execution challenges, but strong cash flow and dividend payments bolster investor appeal.